• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor, pharmacist or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

1. What Ventavis is and what it is used for
2. What you need to know before you use Ventavis
3. How to use Ventavis
4. Possible side effects
5. How to store Ventavis
6. Contents of the pack and other information

The active substance of Ventavis is iloprost. It imitates a natural substance in the body called prostacyclin. Ventavis inhibits unwanted blocking or narrowing of blood vessels and allows more blood to flow through the vessels.

Ventavis is used to treat moderate cases of primary pulmonary hypertension (PPH) in adult patients.

PPH is a category of pulmonary hypertension where the cause of the high blood pressure is not known.

This is a condition where blood pressure is too high in the blood vessels between the heart and the lungs.

Ventavis is used to improve exercise capacity (the ability to carry out physical activity) and symptoms.

Breathing in the mist carries Ventavis to the lungs, where it can work most effectively in the artery between heart and lungs. Improved blood flow leads to a better supply of oxygen to the body and reduced strain on the heart.

• if you are allergic to iloprost or any of the other ingredients of this medicine (listed in section 6),
• if you are at risk of bleeding– for example, if you have an active ulcer of the stomach or of the first part of the small intestine (duodenal ulcers), if you have suffered a physical injury (trauma), if you are at risk of bleeding within the skull,
• if you have a heart problem, such as
  • poor blood flow to the heart muscles (severe coronary heart disease or unstable angina). Symptoms can include chest pain,
  • a heart attack within the last six months,
  • a weak heart (decompensated cardiac failure) which is not under close medical observation,
  • severe unstable heartbeat,
  • a defect of the heart valves (inborn or acquired) that causes the heart to work poorly (not related to pulmonary hypertension),
• if you have had a stroke within the last 3 months, or any other occurrence that reduced the blood supply to the brain (e.g. transient ischaemic attack),
• if your pulmonary hypertension is due to a blocked or narrowed vein (venous occlusive disease).

Talk to your doctor, pharmacist or nurse before using Ventavis:

• Inhaling Ventavis might trigger breathing difficulties (see section 4), especially in patients with bronchospasm (sudden constriction of the muscles in the walls of the small airways) and wheezing. Tell your doctor, if you have a lung infection, severe asthma, or chronic lung disease (chronic obstructive pulmonary disease). Your doctor will monitor you closely.
• Your blood pressure will be checked before treatment and if it is too low (less than 85 mmHg for the upper value) then therapy with Ventavis should not be started.
• In general, you will need to take special care to try and avoid effects of low blood pressure, such as fainting and dizziness:
  • Tell your doctor if you are taking any other medication because the combined effect with Ventavis may lower your blood pressure further (see below "Other medicines and Ventavis").
  • Stand up slowly when you get out of chairs or bed.
  • If you tend to faint as soon as you get out of bed, it may be helpful to take your first dose of the day while you are still lying down.
  • If you tend to experience fainting episodes, avoid any exceptional straining, for example during physical exertion; it might be useful to inhale Ventavis before.
• Fainting episodes may be due to the underlying disease. Tell your doctor if they get worse. He/she may consider adjusting your dose or changing your treatment.
• If you suffer from a weak heart condition such as right heart failure, and feel that your disease is worsening, tell your doctor. Symptoms can include swelling of feet and ankles, shortness of breath, palpitations, urinating more frequently at night or oedema. Your doctor will consider changing your treatment.
• If you experience difficulty breathing, cough up blood, and/or sweat excessively these may be signs that you have water in the lungs (lung oedema). Stop using Ventavis and tell your doctor immediately. He/she will look for the cause and take appropriate measures.
• If you have liver problems or very severe kidney problems, requiring dialysis, tell your doctor. You may be gradually introduced to the prescribed dose or be prescribed a lower dose of Ventavis than for other patients (see section 3. "How to use Ventavis").

• Do NOT let Ventavis solution come into contact with your skin or eyes.
  If it does, rinse the skin or your eyes immediately with plenty of water.
• Do NOT drink or swallow Ventavis solution.
  If you swallow it accidentally, drink plenty of water and tell your doctor.

The safety and efficacy of Ventavis in children aged up to 18 years have not been established.

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. Ventavis and certain other medicines may affect each other in the way they work in your body.

Tell your doctor if you are taking:

• Medicines used to treat high blood pressure or heart disease, such as
  • beta blockers,
  • nitro-vasodilators,
  • ACE inhibitors.

Your blood pressure may drop much further.

Your doctor may change the dosage.

• Medicines that thin the blood or inhibit blood clotting, this includes
  
  • acetylsalicylic acid (ASA - a compound found in many medicines that lower fever and relieve pain),
  • heparin,
  • coumarin-type anticoagulants, such as warfarin or phenprocoumon,
  • non-steroidal anti-inflammatory drugs,
  • non-selective phosphodiesterase inhibitors, such as pentoxifylline,
  • selective phosphodiesterase 3 (PDE 3) inhibitors, such as cilostazol or anagrelide,
  • ticlopidine,
  • clopidogrel,
  • glycoprotein IIb/IIIa antagonists, such as
    • abciximab,
    • eptifibatide,
    • tirofiban,
  • defibrotide.
  Your doctor will monitor you carefully.

Before taking any medicine ask your doctor or pharmacist, who has more information on medicines to be careful with or avoid when using Ventavis.

Food or drink is not expected to affect Ventavis. However, you should avoid taking food or drink during inhalation.

• If you suffer from pulmonary hypertension, avoid getting pregnant as pregnancy may lead to a worsening of your condition and may even endanger your life.
• If you could get pregnant, use reliable contraception from the time you start treatment and during treatment.
• If you are pregnant, think you might be or are planning to have a baby, tell your doctor straight away. Ventavis should only be used during pregnancy if your doctor decides that the potential benefit outweighs the potential risk to you and the foetus.

It is not known whether Ventavis passes into human milk. A potential risk to the breast-feeding child cannot be excluded and it is preferable to avoid breast-feeding during Ventavis therapy.

Ask your doctor or pharmacist for advice before taking any medicine.

Newborns, infants and pregnant women should not be in the same room while you are inhaling Ventavis.

Ventavis lowers blood pressure and may cause dizziness or light-headedness in some people.

Do not drive or operate any tools or machines if you feel these effects.

Ventavis 10 microgram/ml contains 0.81 mg alcohol (ethanol) in each ml which is equivalent to 0.081% (w/v). The amount of 0.81 mg of alcohol in 1 ml of this medicine is equivalent to less than 1 ml beer or wine.

The small amount of alcohol in this medicine will not have any noticeable effects.

Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

The dose of Ventavis and the duration of treatment that is right for you depend on your individual condition. Your doctor will advise you. Do not change the recommended dose without consulting your doctor first.

Different nebuliser devices can be used to administer Ventavis. Depending on the type of device used and dose prescribed, 1 ml or 2 ml of Ventavis 10 microgram/ml are appropriate.

• Breelib nebuliser

If you are starting Ventavis treatment or if you switch from an alternative device your first inhalation will be with Ventavis 10 microgram/ml (1 ml ampoule with white and yellow rings). If you tolerate this dose well, your next inhalation will be with Ventavis 20 microgram/ml (ampoule with yellow and red rings). You should continue on this dose.

If you cannot tolerate inhalation of Ventavis 20 microgram/ml talk to your doctor who may decide that you should take Ventavis 10 microgram/ml (1 ml ampoule).

Most people will have 6 to 9 inhalation sessions spread throughout the day. One inhalation session with Breelib will usually last about 3 minutes.

Your doctor will supervise your treatment when you start using the Breelib nebuliser to ensure that you tolerate dose and speed of inhalation well.

• I-Neb AAD nebuliser (1 ml ampoule with white and yellow rings)

In general, when starting Ventavis treatment the first inhaled dose should be 2.5 microgram iloprost as delivered at the mouthpiece. If you tolerate this dose well, your dose should be increased to 5 microgram iloprost and you should continue on this dose. If you are unable to tolerate the 5 microgram dose, the dose should be reduced to 2.5 microgram.

Most people will have 6 to 9 inhalation sessions spread throughout the day. One inhalation session will usually last about 4 to 10 minutes with I-Neb AAD depending on the prescribed dose.

• Venta-Neb nebuliser (2 ml ampoule with white and pink rings)

In general, when starting Ventavis treatment the first inhaled dose should be 2.5 microgram iloprost as delivered at the mouthpiece. If you tolerate this dose well, your dose should be increased to 5 microgram and you should continue on this dose. If you are unable to tolerate the 5 microgram dose, the dose should be reduced to 2.5 microgram.

Most people will have 6 to 9 inhalation sessions spread throughout the day. One inhalation session with Venta-Neb will usually last about 4 to 10 minutes depending on the prescribed dose.

Depending on your individual needs, Ventavis can be used for long term treatment.

There is no need to alter the dose in patients with mild or moderate kidney problems (patients with a creatinine clearance > 30 ml/min).

If you have very severe kidney problems and require dialysis or if you have liver problems, your doctor will introduce you to Ventavis gradually and possibly prescribe fewer daily inhalations. Start therapy by inhaling 2.5 microgram iloprost using 1 ml ampoule of Ventavis 10 microgram/ml (with white and yellow rings). Use dosing intervals of 3 – 4 hours (this corresponds to a maximum of 6 administrations per day). Thereafter, your doctor may cautiously shorten the dosing intervals depending on how you tolerate the treatment. If your doctor decides to further increase the dose up to 5 microgram, again dosing intervals of 3 - 4 hours should be chosen initially and shortened depending on how you tolerate the treatment.

If you feel that the effect of Ventavis is too strong or too weak, talk to your doctor or pharmacist. Ask your doctor to have someone help you become thoroughly familiar with the use of the nebuliser. You should not switch to another nebuliser without consulting the doctor who is treating you.

For each inhalation session you should use a new ampoule of Ventavis. Just before you start to inhale, break the glass ampoule and pour the solution into the medication chamber following the instructions for use of the nebuliser.

Follow carefully the instructions that come with the nebuliser especially the instructions on hygiene and cleaning of the nebuliser.

Always take Ventavis exactly as your doctor has told you.

• Ventavis 10 microgram/ml nebuliser solution is inhaled using the nebulisers your doctor prescribed (either the Breelib, the Venta-Neb or the I-Neb AAD system).
• The nebuliser turns Ventavis solution into a mist which you breathe in through your mouth.
• For the inhalation you should use a mouthpiece to prevent Ventavis coming into contact with your skin. Do not use a facial mask.
• Follow carefully any instructions that come with the nebuliser. Check with your doctor or pharmacist if you are unsure.
• Any Ventavis solution remaining in the nebuliser after inhalation must be thrown away (see section 5).

Room ventilation

Be sure to ventilate or air the room in which you have taken your Ventavis treatment. Other people might accidentally be exposed to Ventavis through the room air. In particular, newborns, infants and pregnant women should not be in the same room while you are inhaling Ventavis.

• Breelib

Fill the medication chamber with Ventavis immediately before use. For filling please follow the instructions for use of the nebuliser.

Device: Breelib

Drug Product: Ventavis 10 mcg/ml (1 ml ampoule with white and yellow rings)

Dose of iloprost at mouthpiece: 2.5 mcg

Estimated inhalation time: 3 minutes

• I-Neb AAD

1. Just before you start to inhale, break the glass ampoule containing 1 ml solution, which has two coloured rings (white - yellow), and pour the complete contents into the nebuliser medication chamber.

2. The pre-set dose provided by the I-Neb AAD system is controlled by the medication chamber in combination with a control disc. There are two different colour coded medication chambers. For each medication chamber there is a corresponding colour coded control disc:

• For the 2.5 microgram dose the medication chamber with the red coloured latch is used together with the red control disc.
• For the 5 microgram dose the medication chamber with the purple coloured latch is used together with the purple control disc.

3. In order to ensure that you receive the prescribed dose, check the colour of the medication chamber and the colour of the control disc. They should both have the same colour, either red for the 2.5 microgram dose or purple for the 5 microgram dose.

Device: I-Neb AAD

Dose of iloprost at mouthpiece: 2.5 micrograms

Estimated Inhalation time: 3.2 min

Device: I-Neb AAD

Dose of iloprost at mouthpiece: 5 micrograms

Estimated Inhalation time: 6.5 min

Drug product: Ventavis 10 mcg/ml

Ampoule coloured ring: 1 ml ampoule white - yellow ring

Dosage: 2.5 mcg

Medication chamber latch: red

Control disc: red

Dosage 5 mcg

Medication chamber latch: purple

Control disc: purple

Venta-Neb

1. Just before you start to inhale, break the glass ampoule containing 2 ml solution, which has two coloured rings (white-pink), and pour the complete contents into the nebuliser medication chamber.

2. Two programmes can be operated:

3. Your doctor will adjust Venta-Neb to the programme you need to receive the dose prescribed for you.

• P1 Programme 1: 5 microgram active substance on the mouth piece 25 inhalation cycles.
• P2 Programme 2: 2.5 microgram active substance on the mouth piece 10 inhalation cycles.

4. You should use the green baffle plate to obtain the optimal droplet size for the administration of Ventavis.

Device: Venta-Neb

Dose of iloprost at mouthpiece: 2.5 micrograms

Estimated Inhalation time: 4 min

Device: Venta-Neb

Dose of iloprost at mouthpiece: 5 micrograms

Estimated Inhalation time: 8 min

For further details please refer to the instruction manual of the nebuliser device or ask your doctor.

Using more Ventavis than you should may lead to dizziness, headache, flushing (reddening of the face), nausea (feeling sick), jaw pain or back pain.

You may also experience a decrease or an increase in blood pressure, bradycardia (reduced heart rate), tachycardia (increased heart rate), vomiting, diarrhoea or limb pain. If any of these happen when you have used more Ventavis than you should:

• stop the inhalation session
• talk to your doctor

Your doctor will monitor you and treat any resulting symptoms. A specific antidote is not known.

Do not take a double dose to make up for a forgotten dose. Please ask your doctor what you should do.

If you stop or wish to stop treatment, discuss it with your doctor first.

• Swelling, mainly of the ankles and legs, due to fluid retention (peripheral oedema) is a very common symptom of the illness itself but can also occur during treatment with Ventavis.

If you get any side effects talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

• The active substance is iloprost.

1 ml solution contains 10 microgram iloprost (as iloprost trometamol).

Each ampoule with 1 ml contains 10 microgram iloprost.

Each ampoule with 2 ml contains 20 microgram iloprost.

• The other ingredients are trometamol, ethanol, sodium chloride, hydrochloric acid for pH adjustment, and water for injections.

Ventavis is a clear, colourless nebuliser solution for inhalation with the Breelib, the I-Neb or the Venta-Neb nebuliser.

Ventavis 10 microgram/ml is provided in colourless ampoules, containing either 1 ml or 2 ml nebuliser solution.

Ventavis 10 microgram/ml is available in the following packs:

• 1 ml ampoules for use with Breelib or I-Neb nebulisers:
  • Pack containing 30 or 42 ampoules for use with the Breelib and I-Neb nebuliser.
  • Multipack containing 168 (4x42) ampoules for use with the Breelib and I-Neb nebuliser.
  • Multipack containing 168 (4x42) ampoules with Breelib consumables set (containing 1 mouthpiece and 1 medication chamber).

The ampoules containing 1 ml are marked with two coloured rings (white - yellow).

• 2 ml ampoules for the use with Venta-Neb:
  • Pack containing 30, 90, 100 or 300 ampoules.
  • Multipack containing 90 (3x30) or 300 (10x30) ampoules.

The ampoules containing 2 ml are marked with two coloured rings (white – pink).

Not all pack-sizes may be marketed.